FindTrial
Sign In

Study on effect of antibiotic amikacin in patient undergoing surgery for perforation of bowel

Amikacin Antibiotic prophylaxis in patient with perforation peritonitis :A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/01/079756
Enrollment
130
Registered
2025-01-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K650- Generalized (acute) peritonitis

Interventions

Intervention1: Amikacin Antibiotic prophylaxis in patient with perforation peritonitis:A Randomized Controlled Trial: Injection amikacin 500mg will be administered intravenously along with injection c

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor
Subhash mishra
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Renal failure Immunosuppressed

Design outcomes

Primary

MeasureTime frame
To compare incidence of superficial deep organ space infection in patient receiving amikacin in addition to the standard ceftriaxone and metronidazole with that of patient receiving only the standard protocol following laparotomy for perforation peritonitisTimepoint: 4 weeks—

Secondary

MeasureTime frame
Surgical site infection, wound dehiscence, readmission, reinterventionTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactSubhash Mishra

JIPMER

debasismbbs@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026